We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current VYGR market cap is 189.95M. The company's latest EPS is USD -1.1774 and P/E is -2.95.
| Quarter End | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 90.06M | 19.52M | 29.58M | 24.63M | 6.28M |
| Operating Income | 54.06M | -16.18M | -15.03M | -13.78M | -38.3M |
| Net Income | 56.4M | -11.33M | -10.14M | -9.04M | -34.49M |
| Year End 31 December 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 171.13M | 37.42M | 40.91M | 250.01M | 80M |
| Operating Income | 27.38M | -73.62M | -50.84M | 122.01M | -83.29M |
| Net Income | 36.74M | -71.2M | -46.41M | 132.33M | -65M |
| Quarter End | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 351.28M | 469.59M | 436.23M | 426.04M | 393.05M |
| Total Liabilities | 114.96M | 128.71M | 100.81M | 95.73M | 93.29M |
| Total Equity | 236.32M | 340.89M | 335.42M | 330.31M | 299.76M |
| Year End 31 December 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 261.58M | 193.86M | 159.36M | 351.28M | 393.05M |
| Total Liabilities | 107.26M | 98.8M | 100.34M | 114.96M | 93.29M |
| Total Equity | 154.32M | 95.06M | 59.02M | 236.32M | 299.76M |
| Quarter End | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | 77.92M | 58.77M | 27.19M | -781k | -15.31M |
| Investing | -141.64M | -96.07M | -132.01M | -67.66M | -94.86M |
| Financing | 33.65M | 112.86M | 113.43M | 113.44M | 114.02M |
| Year End 31 December 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -96.72M | -53.53M | -12.51M | 77.92M | -15.31M |
| Investing | 113M | 65.91M | -7.34M | -141.64M | -94.86M |
| Financing | 3.16M | 612k | 1.11M | 33.65M | 114.02M |
| Market Cap | 189.95M |
| Price to Earnings Ratio | -2.95 |
| Price to Sales Ratio | 2.39 |
| Price to Cash Ratio | 2.68 |
| Price to Book Ratio | 0.64 |
| Dividend Yield | - |
| Shares Outstanding | 55.21M |
| Average Volume (1 week) | 298.08k |
| Average Volume (1 Month) | 398.25k |
| 52 Week Change | -53.38% |
| 52 Week High | 9.55 |
| 52 Week Low | 2.75 |
| Spread (Intraday) | 0.75 (20.83%) |
| Company Name | Voyager Therapeutics Inc |
| Address |
corporation trust center wilmington, delaware 19801 |
| Website | https://www.voyagertherapeutics.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
